X-Vax Technology, headquartered in Jupiter, Florida and founded in 2015, is at the forefront of biotechnology innovation with its focus on developing vaccines for mucosal infections. The company is addressing crucial health challenges by targeting diseases such as herpes, influenza, tuberculosis, and HIV, conditions affecting millions globally. Their pioneering approach induces antibodies aimed at eradicating infected cells, offering a potentially groundbreaking method to enhance immune responses.
The startup received its last known funding of $56.00M in a Series A round dated July 23, 2019. This investment was spearheaded by a consortium of notable investors, including Founders Fund, Connectivity Ventures Fund, Adjuvant Capital, Alexandria Venture Investments, Helicase Venture, Scientia Ventures, Johnson & Johnson Innovation – JJDC, and the Serum Institute of India Pvt. Ltd.. This robust backing underscores investor confidence in X-Vax Technology's potential to transform vaccine development and impact global health.
